Evidence map›Paper›PMID 33240398›Full record

ArticleTherapeutic advances in medical oncology2020

Lactate dehydrogenase kinetics predict chemotherapy response in recurrent metastatic nasopharyngeal carcinoma.

Luo Huang, Adelene Y L Sim, Yongzhong Wu, Zhongguo Liang, Kaiguo Li, Youqin Du, Enya H W Ong, Hong Qi Tan, Joseph T S Wee, Yue Xie and 4 more

Open access · goldAbstract read
In one paragraph

Article in Therapeutic advances in medical oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.9field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 21 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Tumor volume reduction after induction chemotherapy with gemcitabine plus cisplatin in nasopharyngeal carcinoma.European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2023
    Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 4 institutions in 2 countries.

Luo HuangDepartment of Radiation Oncology, Guangxi Medical University Cancer Hospital, Nanning, China.
Adelene Y L SimDivision of Medical Sciences, National Cancer Centre Singapore, Singapore.
Yongzhong WuDepartment of Radiation Oncology, Chongqing University Cancer Hospital, Chongqing, China.
Zhongguo LiangDepartment of Radiation Oncology, Guangxi Medical University Cancer Hospital, Nanning, China.
Kaiguo LiDepartment of Radiation Oncology, Guangxi Medical University Cancer Hospital, Nanning, China.
Youqin DuDepartment of Radiation Oncology, Guangxi Medical University Cancer Hospital, Nanning, China.
Enya H W OngDivision of Radiation Oncology, National Cancer Centre Singapore, Singapore.
Hong Qi TanDivision of Radiation Oncology, National Cancer Centre Singapore, Singapore.
Joseph T S WeeDivision of Radiation Oncology, National Cancer Centre Singapore, Singapore.
Yue XieDepartment of Radiation Oncology, Chongqing University Cancer Hospital, Chongqing, China.
Xiaolei ShuDepartment of Radiation Oncology, Chongqing University Cancer Hospital, Chongqing, China.
Ying WangDepartment of Radiation Oncology, Chongqing University Cancer Hospital, 181 Han Yu Road, Chongqing, 400030, China.
Melvin L K ChuaDivision of Radiation Oncology, National Cancer Centre Singapore, 11 Hospital Crescent, Singapore, 169610, Singapore.ORCID https://orcid.org/0000-0002-1648-1473
Xiaodong ZhuDepartment of Radiation Oncology, Guangxi Medical University Cancer Hospital, 77 He Di Road, Nanning, 530021, China.
Chongqing University · CNGuangxi Medical University · CNDuke-NUS Medical School · SGNational Cancer Centre Singapore · SG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundLactate dehydrogenase (LDH) is a known prognostic biomarker for the endemic variant of nasopharyngeal carcinoma (NPC). Here, we investigate whether serial changes in LDH level between chemotherapy (CT) cycles are associated with tumour response to CT.

methodsPatients with biopsy-proven, recurrent or treatment-naïve metastatic NPC (mNPC) were recruited. All patients had received at least two cycles of platinum-based doublet or triplet CT, with serial assessment of LDH prior to every cycle of chemotherapy (CT1-6). Patients harbouring conditions that affect LDH levels (IU/L) were excluded. Tumour response was assessed after every two cycles of CT by RECIST v1.1.

resultsA total of 158 patients were analysed, including 77 with recurrent and 81 with treatment-naïve mNPC. High pre-CT LDH was associated with an inferior overall survival [hazard ratio 1.93 for ⩾240

conclusionHerein, we characterised the longitudinal variation of LDH in response to CT in mNPC. Our findings suggest the potential utility of interval LDH ratio to predict subsequent tumour response to CT.

Indexed as

biomarker kineticschemotherapylactate dehydrogenasenasopharyngeal carcinomatumour response

Identifiers

PMID33240398
PMCPMC7672732
OpenAlexW3098920734

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.